Market Closed -
Nasdaq
04:00:00 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
2.71
USD
|
+2.26%
|
|
+3.44%
|
-80.66%
|
Fiscal Period: December |
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
374.3
|
90.62
|
-
|
-
|
Enterprise Value (EV)
1 |
374.3
|
90.62
|
90.62
|
90.62
|
P/E ratio
|
-12.1
x
|
-2.83
x
|
-2.39
x
|
-2.52
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2,202
x
|
17,002
x
|
-
|
3.17
x
|
EV / Revenue
|
2,202
x
|
17,002
x
|
-
|
3.17
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
EV / FCF
|
-17.6
x
|
-3.78
x
|
-2.38
x
|
-3.36
x
|
FCF Yield
|
-5.69%
|
-26.5%
|
-41.9%
|
-29.8%
|
Price to Book
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
26,718
|
33,438
|
-
|
-
|
Reference price
2 |
14.01
|
2.710
|
2.710
|
2.710
|
Announcement Date
|
3/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
11.07
|
0.17
|
0.00533
|
-
|
28.55
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-3.013
|
-24.16
|
-25.8
|
-35.68
|
-36.43
|
Operating Margin
|
-
|
-27.22%
|
-14,214.71%
|
-484,127.58%
|
-
|
-127.6%
|
Earnings before Tax (EBT)
1 |
-
|
-4.107
|
-28.3
|
-27.26
|
-35.58
|
-35.88
|
Net income
1 |
-16.38
|
-5.207
|
-28.3
|
-27.26
|
-35.58
|
-35.88
|
Net margin
|
-
|
-47.05%
|
-16,645.29%
|
-511,388.37%
|
-
|
-125.68%
|
EPS
2 |
-0.6000
|
-0.2100
|
-1.160
|
-0.9567
|
-1.133
|
-1.075
|
Free Cash Flow
1 |
-
|
-
|
-21.3
|
-24
|
-38
|
-27
|
FCF margin
|
-
|
-
|
-12,529.41%
|
-450,281.43%
|
-
|
-94.57%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
6/24/22
|
3/29/23
|
3/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.17
|
-
|
-
|
-
|
0.008
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-6.462
|
-5.395
|
-5.307
|
-7.001
|
-8.115
|
-5.831
|
-6.024
|
-6.196
|
-7.031
|
-6.1
|
Operating Margin
|
-3,801.18%
|
-
|
-
|
-
|
-101,437.5%
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-10.36
|
-5.821
|
-5.345
|
-6.767
|
-7.85
|
-6.508
|
-6.633
|
-6.795
|
-7.031
|
-6.1
|
Net income
1 |
-10.36
|
-5.821
|
-5.345
|
-6.767
|
-7.85
|
-6.508
|
-6.633
|
-6.795
|
-7.031
|
-6.1
|
Net margin
|
-6,096.47%
|
-
|
-
|
-
|
-98,125%
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.5300
|
-0.2300
|
-0.2000
|
-0.2500
|
-0.2900
|
-0.2367
|
-0.2233
|
-0.2300
|
-0.2100
|
-0.1800
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/15/23
|
8/14/23
|
11/14/23
|
3/29/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
24.5
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-21.3
|
-24
|
-38
|
-27
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.05
|
1.03
|
0.67
|
1.2
|
3
|
Capex / Sales
|
-
|
0.44%
|
602.94%
|
12,476.55%
|
-
|
10.51%
|
Announcement Date
|
6/24/22
|
3/29/23
|
3/29/24
|
-
|
-
|
-
|
Last Close Price
2.71
USD Average target price
23.5
USD Spread / Average Target +767.16% Consensus |
1st Jan change
|
Capi.
|
---|
| -80.66% | 90.62M | | +11.91% | 118B | | +11.60% | 106B | | -4.68% | 24.28B | | -0.82% | 21.96B | | -10.12% | 18.16B | | -42.12% | 16.37B | | -17.47% | 15.56B | | +2.77% | 13.63B | | +34.58% | 12.27B |
Bio Therapeutic Drugs
|